BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 23632061)

  • 1. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
    Zambra FM; Biolchi V; Brum IS; Chies JA
    Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer.
    Kucukgergin C; Isman FK; Cakmakoglu B; Sanli O; Seckin S
    DNA Cell Biol; 2012 Aug; 31(8):1418-24. PubMed ID: 22612293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia.
    Biolchi V; Silva Neto B; Pianta DB; Koff WJ; Berger M; Brum IS
    Mol Biol Rep; 2013 Mar; 40(3):2749-56. PubMed ID: 23184046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
    Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
    DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological features.
    Samzadeh M; Hasanzad M; Jamaldini SH; Haghdoost AA; Afshari M; Ziaee SA
    Urol J; 2012; 9(4):691-9. PubMed ID: 23235975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
    Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
    Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia.
    Pang Y; Li H; Gong Y; Jing S; Peng C; Liu W; Zhao Y; Wang H; Kaushik D; Rodriguez R; Wang Z
    Oncol Rep; 2019 Apr; 41(4):2491-2501. PubMed ID: 30816510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer.
    Wang L; Habuchi T; Tsuchiya N; Mitsumori K; Ohyama C; Sato K; Kinoshita H; Kamoto T; Nakamura A; Ogawa O; Kato T
    Cancer Res; 2003 Aug; 63(15):4407-11. PubMed ID: 12907612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variations in CC chemokine receptors and hypertension.
    Zhang M; Ardlie K; Wacholder S; Welch R; Chanock S; O'Brien TR
    Am J Hypertens; 2006 Jan; 19(1):67-72. PubMed ID: 16461193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of CCR5-delta32, CCR2-64I and SDF-1-3'A polymorphic alleles on human immunodeficiency virus 1 (HIV-1) infection in the Polish population].
    Wasik TJ; Smoleń J; Kruszyński P; Bratosiewicz-Wasik J; Beniowski M
    Wiad Lek; 2005; 58(9-10):500-7. PubMed ID: 16529059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
    Safarinejad MR; Shafiei N; Safarinejad S
    Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenetics of prostate cancer and benign hyperplasia--the potential use of an HLA-G variant as a tag SNP for prostate cancer risk.
    Zambra FM; Biolchi V; de Cerqueira CC; Brum IS; Castelli EC; Chies JA
    HLA; 2016 Feb; 87(2):79-88. PubMed ID: 26889902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chemokine receptor CCR2 and CCR5 gene polymorphism on allograft outcome in North Indian renal transplant recipients.
    Singh R; Kapoor R; Srivastava A; Mittal RD
    Scand J Immunol; 2009 Jan; 69(1):51-6. PubMed ID: 19037908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association of human chemokine receptor gene polymorphisms CCR2-64I and CCR5-Delta32 with autoimmune Addison's disease.
    Gambelunghe G; Ghaderi M; Gharizadeh B; Brozzetti A; Tortoioli C; Del Sindaco P; Sanjeevi CB; Hjelmström P; Sirsjö A; Nyren P; Santeusanio F; Falorni A
    Eur J Immunogenet; 2004 Apr; 31(2):73-6. PubMed ID: 15086346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of CCR5-Delta32, CCR5m303A, CCR2-64I and SDF1-3'A in HIV-1 infected and uninfected high-risk Uighurs in Xinjiang, China.
    Tan XH; Zhang JY; Di CH; Hu AR; Yang L; Qu S; Zhao RL; Yang PR; Guo SX
    Infect Genet Evol; 2010 Mar; 10(2):268-72. PubMed ID: 19958843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of CCR5-Δ32 against HIV infection by the heterosexual mode of transmission in a Polish population.
    Zwolińska K; Knysz B; Rybka K; Pazgan-Simon M; Gąsiorowski J; Sobczyński M; Gładysz A; Piasecki E
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):54-60. PubMed ID: 22957692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.